Page last updated: 2024-11-12

th9507

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tesamorelin: a peptide; a stabilized analogue of the growth hormone releasing factor; aimed at reducing excess abdominal fat or VAT in lipodystrophy and HIV patients [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tesamorelin : A polypeptide that is a synthetic analogue of human GRF (Growth Releasing Factor) comprised of the 44 amino-acid sequence of human GRF with a hex-3-enoyl moiety attached to the tyrosine residue at the N-terminal part of the molecule. It is used to stimulate human GRF receptors. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16137828
MeSH IDM0457285

Synonyms (11)

Synonym
th9507
218949-48-5
tesamorelin
egrifta
tesamorelin [usan:inn]
mqg94m5eeo ,
unii-mqg94m5eeo
gtpl6959
(3e)-hex-3-enoylsomatoliberin
DTXSID00583207
804475-66-9

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Although TH9507 was well tolerated by both rats and dogs, a more pronounced anabolic effect and more evident (reversible) adverse effects (liver and kidney findings, anaemia, clinical chemistry changes, organ weight effects) were observed in dogs after repeat daily subcutaneous injections, which were attributed to prolonged exposure to supraphysiological levels of growth hormone and/or IGF-1."( Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.
Brazeau, P; Dubreuil, P; Fennell, S; Ferdinandi, ES; High, K; Procter, B, 2007
)
0.99
"Safety included adverse events and glucose parameters."( Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
Allas, S; Berger, D; Brown, S; Falutz, J; Fessel, J; Grinspoon, S; Kotler, D; Mamputu, JC; Potvin, D; Richmond, G; Somero, M; Turner, R, 2008
)
0.35
" The prevalence of adverse events and serious adverse events during the extension phase was comparable with the initial phase."( Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
Allas, S; Berger, D; Brown, S; Falutz, J; Fessel, J; Grinspoon, S; Kotler, D; Mamputu, JC; Potvin, D; Richmond, G; Somero, M; Turner, R, 2008
)
0.35

Pharmacokinetics

ExcerptReferenceRelevance
" Age, body size measures, race and health status were not related to tesamorelin pharmacokinetic parameters within the range of covariates studied."( Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Barrière, O; Boudreault, S; González-Sales, M; Mamputu, JC; Nekka, F; Tanguay, M; Tremblay, PO, 2015
)
0.42
"The objective of this analysis was to characterize the time course of selected pharmacodynamic (PD) markers of tesamorelin: growth hormone (GH) and insulin-like growth factor (IGF-1) concentrations in HIV-infected patients and healthy volunteers."( Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Barrière, O; Boudreault, S; González-Sales, M; Mamputu, JC; Nekka, F; Tanguay, M; Tremblay, PO, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" The bioavailability by the inhaled route was 41% relative to subcutaneous dosing, with an absolute bioavailability estimated at 13%."( Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.
Abribat, T; Darby, I; Dubreuil, P; Ferdinandi, ES; Hardy, JG; Jansen, M, 2004
)
0.64

Dosage Studied

ExcerptRelevanceReference
" Blood samples were collected at selected sampling times after dosing and plasma levels of TH9507 were measured by radioimmunoassay."( Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.
Abribat, T; Darby, I; Dubreuil, P; Ferdinandi, ES; Hardy, JG; Jansen, M, 2004
)
0.86
" Optimal therapeutic dosing and treatment duration, though, are not yet known."( Pathogenesis and treatment of HIV lipohypertrophy.
Glesby, MJ; Leung, VL, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (30.36)29.6817
2010's34 (60.71)24.3611
2020's5 (8.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (31.34%)5.53%
Reviews16 (23.88%)6.00%
Case Studies2 (2.99%)4.05%
Observational0 (0.00%)0.25%
Other28 (41.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]